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Introduction 
healthcare systems have two main health-related goals: 
increasing the quality of life and years of healthy life (13). 
Measuring the health-related quality of life (hRqol) gives 
valuable information regarding the healthcare progress. 
HRQoL is a multi-dimensional concept that includes domains 
associated with physical, mental, emotional and social 
functioning. It goes beyond direct measures of population 
health, life expectancy and causes of death, and focuses on 
the impact that the health status has on the quality of life, 
evaluating the patient status before, during and after treatment 
(9). According to a study on the HRQoL in patients with rare 
diseases (chronic myeloid leukemia, Gaucher disease and 
cystic fibrosis), although some rare diseases do not affect life 
expectancy, most of them lead to physical, emotional and/or 
psychosocial disorders (14).
Rare diseases are pathological conditions that affect a 
relatively small group of the human population. These diseases 
are defined as life-threatening or chronically debilitating, 
severely reducing the quality and length of life (1, 10). 
Currently, there are between 6000 and 8000 distinct rare 
diseases (5860 of them are listed in the Orphanet database), 
affecting between 6 % and 8 % of the world population (1, 
3). the governments in many countries, such as the USA, 
Australia, Japan and the European Union member-states, 
introduced specific legislation regulating the rare disease drugs 
and orphan drugs, indicated for treatment of rare diseases (1). 
Since its introduction in 1980, SF-36 became one of the most 
frequently used multifaceted measures of quality of life (4). Its 
application in patients with rare diseases is a suitable approach 
to estimate the quality of life, a fact confirmed by our study as 
well. 
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ABSTRACT 
The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), 
Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled 
retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University 
Hospital “Alexandrovska” in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from 
the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 
9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher 
disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 
years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between 
the average monthly pharmacotherapy costs for the observed period was revealed. In all patients the quality of life was below 
the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were 
observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of 
quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of 
life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators 
only in the patients with CML. The correlation between the pharmacotherapy costs and physiological functions in patients with 
CML was positive, i.e. higher costs improved this indicator. The pharmacotherapy costs were high, the average values for the 
three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January–March 2011 for patients with CF, BGN 
32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The 
quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, 
respectively, from a maximum of 100.
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Cystic fibrosis (CF) is an inherited rare disease of mucous 
and sweat glands. It affects mostly the lungs, pancreas, liver, 
intestines, sinuses, and reproductive organs and is a chronic 
progressive disease leading to multiorgan failure (7).The care 
for a child with CF is complex and Family Service Agencies are 
needed to help the family to solve different kind of problems 
connected with the disease (15).
Gaucher disease is an autosomal recessive lipid storage 
disorder cased by a deficient or defective production of 
lysosomal enzyme glucocerebrosidase (GD), resulting in an 
accumulation of  glucocerebroside in the liver, spleen, bone 
marrow and rarely in the nervous system, lungs, kidneys, skin 
etc. Gaucher disease has three clinical subtypes and the most 
common one is the non-neuropathic form (type I), occurring 
in approximately 1 in 50 000 live births (11, 18). The quality 
of life of patients with GD could be impaired because of 
debilitating clinical manifestations. A survey concludes that all 
eight health domains of SF-36 were improved after 2 years of 
treatment with imiglucerase (17).
Chronic myelogenous leukemia (CML) is a blood cancer 
in which too many granulocytes are produced in the marrow 
(8).Clinical outcomes, are improved significantly after 
introduction of tyrosine kinase inhibitors (Imatinib, Dasatinib, 
Nilotinib), e.g. higher levels of complete cytogenetic response 
and improved survival (16).
the aim of our study was to analyze the costs of 
pharmacotherapy and quality of life of patients with cystic 
fibrosis, Gaucher disease and chronic myelogenous leukemia 
in Bulgaria. the study focused on the following questions: i. is 
SF-36 applicable for estimation of the quality of life of patients 
with these three rare diseases in Bulgaria? ii. What are the 
main aspects of quality of life affected by the corresponding 
rare disease and what is their relationship to the cost of 
pharmacotherapy?
Materials and Methods 
The study was conducted in University Hospital 
“Alexandrovska”, which is the largest in Bulgaria, during 
2010 and 2011. The data on pharmacotherapy costs were 
collected retrospectively. A prospective quality of life survey 
was conducted with the short version of the SF-36 form – a 
questionnaire introduced by McDowell, which is used to 
estimate the hqol through nine multi-item dimensions 
covering physical activities, role limitations, bodily pain, 
social functioning, general mental health, role limitations due 
to emotional problems, vitality (energy or fatigue), general 
health perceptions and health status compared with the status 
reported for the previous year (4, 9). For each dimension, item 
scores were coded, summed, and transformed onto a scale from 
0 (worst health) to 100 (best health), based on the patients’ 
answers to 11 questions. The SF-36 was previously used and 
validated in Bulgaria for patients with chronic kidney diseases 
and after kidney transplantation (5). Five patients with CF, 
three patients with GD and ten patients with CML receiving 
their medicines from the hospital pharmacy at Hospital 
“Alexandrovska” were interviewed.
The average monthly pharmacotherapy cost for the three 
diagnoses were calculated based on data extracted from the 
hospital registries and covering the studied period: 2010 and 
January–March 2011.
Descriptive statistics, one-way ANOVA analysis and 
Spearman correlation analysis were performed to evaluate the 
statistical significance of the differences in the collected HQoL 
data.
Results and Discussion
Pharmacotherapy costs for the monitored diseases
Currently, there is no treatment for cystic fibrosis (CF). 
However, specialized pharmacotherapy with antibiotics, 
vitamins and other food supplements, enzymes, and inhalers, 
along with proper nutrition, can improve the quality and 
length of life for patients with CF (7). All patients with CF 
included in this study were treated with dornase alfa (highly 
purified solution of recombinant human deoxyribonuclease I 
[rhDNase]), inhaled tobramycin and enzymes (concentrated 
pancreatin-providing enzymes) for the entire period of the 
study. The patients with GD received enzyme replacement 
therapy with intravenous recombinant glucocerebrosidase 
(imiglucerase), and the treatment of patients with CML 
included BCR-ABL tyrosine kinase inhibitors: imatininb, 
dasatininb and nilotinib (for imatininb-resistant patients) (2, 
12). Nilotinib, a new targeted drug developed to treat imatinib-
resitant patients with CML, was prescribed only to 10 % of the 
affected patients in 2010 (Table 1).
The pharmacotherapy cost of patients with GD was 
associated with the highest value, followed by that of patients 
with CF and CML. No statistically significant difference was 
observed between the mean monthly cost of therapy per patient 
during the two observed periods: 2010 and January–March 
2011 (Table 2).
Quality of life
All observed 18 patients were inquired with the short version 
of SF-36. The number of women and men did not differ 
significantly between the groups of patients. Ten patients were 
with CML, five with CF and three with GD. The percentage 
of male patients was 70 %, 40 % and 66.7 % for each group, 
respectively. The female patients were 30 %, 60 % and 33.3 %, 
accordingly. the average age of the women with cF was 35 
years and that of the men, 30 years. the average age of the 
patients with GD was 25 years, and 50 years for the CML 
patients.
In all patient groups, the average quality of life was lower 
than the maximum possible value of 100 points in all domains. 
The differences in the quality of life between the different 
diseases were statistically significant (ANOVA, p = 0.0076). 
The patients with cystic fibrosis scored lower values for most 
indicators of quality of life: role limitations, bodily pain, social 
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TABLE 1
Relative share of prescribed medicines per diagnosis 
Condition 2010 2011 
CF dornase alpha, tobramycin, enzymes 100 % dornase alpha, tobramycin, enzymes 100 %
GD imiglucerase 100 % imiglucerase 100 %
CML
Imatinib 60 % Imatinib 50 %
Dasatinib 30 % Dasatinib 50 %
Nilotinib 10 %   
TABLE 2
Mean monthly pharmacotherapy costs for the monitored diagnoses 
Condition Mean monthly costs 2010 Mean monthly costs Jan–Mar. 2011
One-way ANOVA 
(р)
CF 9221.612 8254.639 0.516616
Gaucher disease 32954.08 no 
CML 6389.378 6591.19 0.750068
TABLE 3
Descriptive statistics – cystic fibrosis and Gaucher disease
Мinimum Maximum Mean Std. deviation
PhysFunc 0.00 100.00 62.3309 37.66416
Rolelim 0.00 100.00 44.4444 48.05234
Pain 22.50 100.00 67.000 24.90607
SocAct 22.50 100.00 70.8333 29.97395
Psychhealth 32.00 92.00 71.5556 19.22961
EmotProb 0.00 100.00 55.5444 47.14046
VitEnFat 25.00 65.00 50.5556 13.33333
Generhealt 5.00 85.00 39.4444 26.27314
healthPrYear 50.00 100.00 66.6667 21.65064
TABLE 4
Descriptive statistics – chronic myeloid leukemia
Мinimum Maximum Mean Std. deviation
PhysFunc 0.00 100.00 75.5100 30.65980
Rolelim 0.00 100.00 77.5000 41.58325
Pain 32.50 100.00 82.5000 24.77678
SocAct 22.50 100.00 71.2500 27.03521
Psychhealth 28.00 88.00 62.4000 21.09871
EmotProb 0.00 100.00 76.6500 35.32041
VitEnFat 30.00 65.00 46.0000 10.21981
Generhealt 30.00 90.00 55.0000 17.79513
healthPrYear 25.00 100.00 62,5000 21.24591
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functioning, role limitations due to emotional problems, and 
general mental health (Fig. 1, Table 3 and Table 4).
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Fig. 1. Average value of SF-36 domains in the three studied groups of patients.
This can be explained by the fact that CF is a chronic 
progressive disease, significantly deteriorating the performance 
of daily activities for which there is only supportive care. 
The higher mean values of HQoL in patients with CML were 
probably due to the prescribed pharmacotherapy, which, as 
per the published scientific data, ensures long-term survival of 
over 5 years (6).
We found a correlation between the mean cost of 
pharmacotherapy and the mean HQoL in all three groups 
(Тable  5), which showed that the quality of life depended 
on the amount of the pharmacotherapy costs. To determine 
what indicators of quality of life change when the costs of 
pharmacotherapy vary, we conducted a Spearman correlation 
analysis.
No correlations were found between the different aspects 
of quality of life and the patients’ characteristics. Correlations 
existed only for particular quality characteristics, but they 
were logical, having in mind the interconnection of the survey 
questions, and they were not discussed either in the group of 
patients with CF, or in the group GD (Table 6).
In patients with CML, there was a positive Spearman 
correlation between the pharmacotherapy costs and 
physiological functions, i.e. the cost increase was found to 
improve this indicator, while a negative Spearman correlation 
was found between the pharmacotherapy costs and pain and 
mental health, which were obviously negatively affected 
(Table 6 and Table 7).
Final remarks
the results of our study give additional evidence for 
significantly reduced quality of life of patients suffering 
TABLE 5
Correlation between HQoL and pharmacotherapy costs 
Condition Mean HQoL Mean monthly costs 2011 One way ANOVA (р)
cF 53.7484 8254.64
р < 0.05Gaucher disease 65.0333 32954.08
cMl 67.7011 6591.19
TABLE 6
Correlation between mean HQoL and pharmacotherapy costs 
Condition Mean HQoL Mean monthly costs Jan-Mar. 2011
Spearman correlation 
coefficient 
cF 53.7484 8254.639 no
Gaucher disease 65.0333 32954.08 no
cMl 67.7011 6591.19 -0.706;-0.697 
TABLE 7
Correlation between the cost of therapy and QoL for the patients with CML
Correlated variables Spearman correlation coefficient 
Costs for pharmacotherapy and physiological functions 0.673 (0.05 cl)
Costs for pharmacotherapy and pain management -0.706 (0.05 cl)
Costs for pharmacotherapy and mental health -0.697 to -0.803 (0.05 cl)
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from rare diseases (cF, cMl, GD) and high costs of 
pharmacotherapy associated with their treatment. The SF-
36 was found suitable for estimating the quality of life of 
patients with rare diseases: CML, GD and CF. With its 
implementation the health perception in a certain population 
could be measured and analyzed. All indicators of quality of 
life were scored as significantly affected in all three groups 
of patients. The patients with cystic fibrosis were those with 
the lowest values for most indicators, whereas the values of 
HRQoL were higher in the patients with CML. Based on our 
results, we also conclude that there is a correlation between 
physiological functioning and pharmacotherapy costs, between 
pain and pharmacotherapy costs and between mental health 
and pharmacotherapy costs in the patients with CML. Our 
study, however, has some limitations: e.g. the fact that it is not 
a long-term analysis but just a shot of the current state of the 
art. Further inquiries should be done to evaluate the long-term 
HQoL for patients with these three rare diseases in Bulgaria. 
Conclusions
Our study indicates that, despite of the limited number of 
patients with rare diseases, the pharmacotherapy costs are high 
and there is a tendency for these costs to cause a significant 
burden to the health care budget. The study highlights the 
importance and specificity of three rare diseases, the need for 
targeted and sound finance of the expensive pharmacotherapy 
and for improvement of medical care for those patients whose 
quality of life is low and are in need of adequate and quality 
medical care.
To the best of our knowledge, this is the first Bulgarian 
study on the quality of life of patients with cystic fybrosis 
and Gaucher disease. It confirmed that the SF-36 could 
be successfully used in this group of patients as well as for 
comparison with the QoL of patients with chronic kidney 
disease.
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